ENLIVEN THERAPEUTICS, INC. Operating Expenses
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Operating Expenses of $37.21 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- ENLIVEN THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $37.21M, a 30.17% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $27.82M, a 12.21% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $34.28M, a 27.47% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $25.10M, a 7.29% decline year-over-year.
- ENLIVEN THERAPEUTICS, INC. operating expenses for fiscal 2025 was $119.66M, a 14.45% increase from fiscal 2024.
- ENLIVEN THERAPEUTICS, INC. operating expenses for fiscal 2024 was $104.55M, a 25.17% increase from fiscal 2023.
- ENLIVEN THERAPEUTICS, INC. operating expenses for fiscal 2023 was $83.53M, a 115.33% increase from fiscal 2022.
- ENLIVEN THERAPEUTICS, INC. operating expenses for fiscal 2022 was $38.79M.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $37.21M 10-Q · filed 2026-08-05 | $65.03M 10-Q · filed 2026-08-05 | $99.32M derived: sum of 3 quarters · filed 2026-08-05 | $124.41M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $27.82M 10-Q · filed 2026-05-07 | $62.11M derived: sum of 2 quarters · filed 2026-05-07 | $87.20M derived: sum of 3 quarters · filed 2026-05-07 | $115.79M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $34.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $59.38M derived: sum of 2 quarters · filed 2026-03-03 | $87.97M derived: sum of 3 quarters · filed 2026-08-05 | $119.66M 10-K · filed 2026-03-03 | ||||
| 2025-09-30 | $25.10M 10-Q · filed 2025-11-12 | $53.68M derived: sum of 2 quarters · filed 2026-08-05 | $85.37M 10-Q · filed 2025-11-12 | $112.27M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $28.58M 10-Q · filed 2026-08-05 | $60.28M 10-Q · filed 2026-08-05 | $87.17M derived: sum of 3 quarters · filed 2026-08-05 | $114.24M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $31.69M 10-Q · filed 2026-05-07 | $58.59M derived: sum of 2 quarters · filed 2026-05-07 | $85.66M derived: sum of 3 quarters · filed 2026-05-07 | $110.26M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $26.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $53.96M derived: sum of 2 quarters · filed 2026-03-03 | $78.57M derived: sum of 3 quarters · filed 2026-03-03 | $104.55M 10-K · filed 2026-03-03 | ||||
| 2024-09-30 | $27.07M 10-Q · filed 2025-11-12 | $51.67M derived: sum of 2 quarters · filed 2025-11-12 | $77.66M 10-Q · filed 2025-11-12 | $100.39M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | $24.60M 10-Q · filed 2025-08-13 | $50.59M 10-Q · filed 2025-08-13 | $73.32M derived: sum of 3 quarters · filed 2025-08-13 | $97.57M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $25.99M 10-Q · filed 2025-05-14 | $48.72M derived: sum of 2 quarters · filed 2025-05-14 | $72.96M derived: sum of 3 quarters · filed 2025-05-14 | $93.10M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | $22.73M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $46.98M derived: sum of 2 quarters · filed 2025-03-13 | $67.11M derived: sum of 3 quarters · filed 2025-03-13 | $83.53M 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | $24.25M 10-Q · filed 2024-11-13 | $44.38M derived: sum of 2 quarters · filed 2024-11-13 | $60.80M 10-Q · filed 2024-11-13 | $70.96M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $20.13M 10-Q · filed 2024-08-13 | $36.55M 10-Q · filed 2024-08-13 | $46.72M derived: sum of 3 quarters · filed 2024-08-13 | $57.65M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $16.42M 10-Q · filed 2024-05-14 | $26.58M derived: sum of 2 quarters · filed 2024-05-14 | $37.52M derived: sum of 3 quarters · filed 2024-05-14 | $46.53M derived: sum of 4 quarters · filed 2024-05-14 | ||||
| 2022-12-31 | $10.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $21.10M derived: sum of 2 quarters · filed 2024-03-14 | $30.11M derived: sum of 3 quarters · filed 2024-03-14 | $38.79M 10-K · filed 2024-03-14 | $34.27M 10-K · filed 2023-02-10 | |||
| 2022-09-30 | $10.93M 10-Q · filed 2023-11-09 | $4.83M 10-Q · filed 2022-10-25 | $19.95M derived: sum of 2 quarters · filed 2023-11-09 | $28.63M 10-Q · filed 2023-11-09 | $31.01M 10-Q · filed 2022-10-25 | $16.28M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $9.02M 10-Q · filed 2023-08-10 | $11.52M 10-Q · filed 2022-08-03 | $17.69M 10-Q · filed 2023-08-10 | $26.18M 10-Q · filed 2022-08-03 | $5.35M derived: sum of 3 quarters · filed 2023-08-10 | $19.01M derived: sum of 4 quarters · filed 2023-08-10 | ||
| 2022-03-31 | $8.68M 10-Q · filed 2023-05-11 | $14.66M 10-Q · filed 2022-05-06 | -$3.67M derived: sum of 2 quarters · filed 2023-06-23 | $9.99M derived: sum of 3 quarters · filed 2023-06-23 | $23.16M derived: sum of 4 quarters · filed 2023-06-23 | |||
| 2021-12-31 | -$12.35M derived: 8-K 12 month − 10-Q 9 month · filed 2023-06-23 | $1.31M derived: sum of 2 quarters · filed 2023-06-23 | $14.48M derived: sum of 3 quarters · filed 2023-06-23 | $24.76M 8-K · filed 2023-06-23 | $51.44M 10-K · filed 2022-03-15 | |||
| 2021-09-30 | $13.66M 10-Q · filed 2022-10-25 | $26.83M derived: sum of 2 quarters · filed 2022-10-25 | $37.11M 10-Q · filed 2022-10-25 | $48.66M derived: sum of 4 quarters · filed 2022-10-25 | ||||
| 2021-06-30 | $13.17M 10-Q · filed 2022-08-03 | $23.45M 10-Q · filed 2022-08-03 | $35.00M derived: sum of 3 quarters · filed 2022-08-03 | $47.49M derived: sum of 4 quarters · filed 2022-08-03 | ||||
| 2021-03-31 | $10.28M 10-Q · filed 2022-05-06 | $21.83M derived: sum of 2 quarters · filed 2022-05-06 | $34.32M derived: sum of 3 quarters · filed 2022-05-06 | $44.63M derived: sum of 4 quarters · filed 2022-05-06 | ||||
| 2020-12-31 | $11.55M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $24.04M derived: sum of 2 quarters · filed 2022-03-15 | $34.35M derived: sum of 3 quarters · filed 2022-03-15 | $41.70M 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | $12.49M 10-Q · filed 2021-11-09 | $22.80M derived: sum of 2 quarters · filed 2021-11-09 | $30.15M 10-Q · filed 2021-11-09 | $37.63M derived: sum of 4 quarters · filed 2021-11-09 | ||||
| 2020-06-30 | $10.30M 10-Q · filed 2021-08-06 | $17.65M 10-Q · filed 2021-08-06 | $25.14M derived: sum of 3 quarters · filed 2021-08-06 | $32.02M derived: sum of 4 quarters · filed 2021-08-06 | ||||
| 2020-03-31 | $7.35M 10-Q · filed 2021-05-11 | $14.84M derived: sum of 2 quarters · filed 2021-05-11 | $21.72M derived: sum of 3 quarters · filed 2021-05-11 | $27.27M derived: sum of 4 quarters · filed 2021-05-11 | ||||
| 2019-12-31 | $7.48M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | $14.37M derived: sum of 2 quarters · filed 2021-03-05 | $19.92M derived: sum of 3 quarters · filed 2021-03-05 | $24.12M 10-K · filed 2021-03-05 | ||||
| 2019-09-30 | $6.88M 10-Q · filed 2020-11-05 | $12.44M derived: sum of 2 quarters · filed 2020-11-05 | $16.63M 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | $5.56M 10-Q · filed 2020-08-14 | $9.75M 10-Q · filed 2020-08-14 | ||||||
| 2019-03-31 | $4.19M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |